Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 3,284 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MRI Study Clear all
Recruiting Not applicable Interventional

Snacking Effects on the Brain Response to Foods and Satiety During Dieting

NCT07428187
View directory record Official record
Conditions
Overweight/Obesity
Interventions
Snack Type 1: Walnuts, Snack Type 2: Pretzels
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Phase 1 Interventional

68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

NCT04216134
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma
Interventions
Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography
Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Phase 2 Interventional

ReoPro and Retavase to Treat Acute Stroke

NCT00046293
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
Reopro, Retrovase
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 29, 2026, 6:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer

NCT03050463
View directory record Official record
Conditions
Healthy Subject, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Biospecimen Collection, Functional Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 29, 2026, 6:39 PM EDT
Completed No phase listed Observational

Effect of MitraClip on Acute and Chronic Reverse Cardiac Remodeling Assessed by CMR: The MITRA-REVERSE Study

NCT02924363
View directory record Official record
Conditions
Mitral Regurgitation
Interventions
Cardiac MRI with or without contrast dye, Blood sample
Diagnostic Test
Lead sponsor
Dipan Shah
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Clitoral Location in Relation to Sexual Function Using Pelvic Imaging

NCT01195701
View directory record Official record
Conditions
Female Sexual Dysfunction, Anorgasmia
Interventions
Not listed
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 29, 2026, 6:39 PM EDT
Active, not recruiting Phase 2 Interventional

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

NCT03181867
View directory record Official record
Conditions
Prostate Neoplasms, Prostatic Cancer, Prostate Cancer, Cancer Of Prostate, Metastatic Prostate Cancer
Interventions
18F-DCFPyL, 18F-FDG, PSMA-11
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Recruiting Phase 1 Interventional

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

NCT04732065
View directory record Official record
Conditions
Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Recurrent Malignant Central Nervous System Neoplasm, Spinal Cord Glioma, World Health Organization (WHO) Grade III Glioma, CNS Tumor, Central Nervous System Tumor
Interventions
ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS)
Drug · Radiation · Procedure
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
2 Years to 21 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Recruiting Phase 2 Interventional

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

NCT07042295
View directory record Official record
Conditions
Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma
Interventions
Amivantamab and Recombinant Human Hyaluronidase, Biospecimen Collection, Cetuximab, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
55
States / cities
Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Basic Research Study to Examine the Relation Between Muscle Insulin Resistance and Lipid Production in the Liver.

NCT02196051
View directory record Official record
Conditions
Insulin Resistance
Interventions
one bout of 45 minutes exercise
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Nitrous Oxide Neuroimaging

NCT06702631
View directory record Official record
Conditions
Anesthesia, Pain, Amnesia
Interventions
Nitrous oxide, Peripheral Nerve Stimulation
Drug · Device
Lead sponsor
Keith M Vogt
Other
Eligibility
18 Years to 59 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Not yet recruiting Phase 2 Interventional

Brain Imaging of DSP-2342

NCT07850102
View directory record Official record
Conditions
SCHIZOPHRENIA 1 (Disorder)
Interventions
DSP-2342
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

The Effect of Transcutaneous Magnetic Stimulation on Acute Pain.

NCT03777137
View directory record Official record
Conditions
Pain Perception
Interventions
TMS (Rapid2, Magstim Corp)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Not applicable Interventional

MR Guided Focused Ultrasound for Treatment of Neuropathic Pain

NCT03111277
View directory record Official record
Conditions
Severe Neuropathic Pain Due to Radiculopathy or Radicular Injury, Spinal Cord Injuries, Phantom Limb Pain
Interventions
Experimental: ExAblate Transcranial treatment
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 29, 2026, 6:39 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cediranib Maleate, Computed Tomography, Echocardiography Test, Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
337
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 256 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Recruiting Phase 1Phase 2 Interventional

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

NCT07012031
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sotorasib, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Sacramento, California • Tampa, Florida • Wesley Chapel, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Phase 2 Interventional

Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)

NCT06855628
View directory record Official record
Conditions
Glioma, GBM
Interventions
[6,6-²H₂]-Glucose
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

NCT06400251
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Recruiting No phase listed Observational

fMRI Accelerated TMS Depression

NCT06562153
View directory record Official record
Conditions
Depression
Interventions
Neuroimaging with Magnetic Resonance Imaging (MRI)
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 29, 2026, 6:39 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

NCT06308822
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Erdafitinib, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

ZTE MRI Pulse Sequence Use for Visualization of Bone Cement, Breast Biopsy Markers

NCT06873802
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Phase 2 Interventional

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders

NCT05064319
View directory record Official record
Conditions
Bipolar Disorder, Cannabis Use, Schizoaffective Disorder, Bipolar Type, Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study To Analyze Memory/Thinking Problems In Older Adults After Surgery

NCT01786577
View directory record Official record
Conditions
Post-Operative Cognitive Decline in Older Adults
Interventions
Magnetic Resonance Imaging, Cognitive assessment testing
Other · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
60 Years and older
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 29, 2026, 6:39 PM EDT
Recruiting Phase 1 Interventional

Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma

NCT07145112
View directory record Official record
Conditions
Glioblastoma
Interventions
Laser interstitial thermal therapy, Lomustine
Procedure · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 6:39 PM EDT